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The distribution of the prohormone convertases, PCl13, PC2 and PC5/6, was determined by immunoblotting in two cell lines. In aTCl-6 cells, 
the proglucagon processing occured according to the pancreatic A-cell type.. In STC-1 cells, proglucagon was processed in a manner eminiscent of
the intestinal L-cell type. PC113 was undetectable in both proglucagon processing cell lines whereas PC2 displayed a strong immunostaining in the 
ccTCl-6 cells and was barely detectable in the STC-1 cells. PC516 was detected as a 70 kDa protein in both cell lines. These results uggest a possible 
role of PC2 in the processing of proglucagon i to glucagon in the A-cells, whereas in L-cells it would require still undetermined endoproteases. 
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1. Introduction 
A single gene encoding proglucagon is expressed in 
A-cells of the pancreatic islets, in intestinal L-cells, in a 
few cells of the gastric mucosa and in neurons of the 
hypothalamus and brainstem [l-3]. Results of analysis 
of these tissues have provided evidence for a tissue-spe- 
cific post-translational processing of proglucagon. In A- 
cells, proglucagon maturation produces essentially glu- 
cagon and the major proglucagon fragment (Fig. 1) [4,5] 
whereas in L-cells and in the brain, it is processed into 
the glucagon-containing peptides glicentin, oxyntomod- 
ulin [1,6] and in two glucagon-like pcptides 1 and 2 
(GLP-1 and GLP-2) [1,5,7]. GLP-1 is further processed 
by N-terminal deletion of six amino acids into the biolog- 
ically active peptides (tGLP-1) [8,9]. This remarkable 
tissue-specific processing of proglucagon, which pro- 
vides a mechanism to increase the diversity of bioactive 
molecules generated from a single precursor, might be 
determined by the restriction of different processing en- 
zymes to defined cell types. 
Several endopeptidases implicated in the processing of 
precursor proteins have been identified by cDNA clon- 
ing and belong to the subtilisin family of serine pro- 
teinases [lo]. Two main endopeptidases, PC1/3 and PC2 
have been described so far in endocrine and neuroendo- 
crine cells [l l-131 and were proposed to be implicated in 
the maturation of several prohormones [14-161. Further- 
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more, it has been suggested that cell-specific prohormone 
processing is likely to be the result of differential expres- 
sion of these two prohormone convertases [15]. A new 
member of this family, PC5/6, mainly localized in the 
epithelial cells of the small intestine and in the adrenal 
[ 17,181 might also be responsible for the maturation of 
gastrointestinal peptides instead of PC1/3 [18]. To ad- 
dress the enzymatic basis for the tissue specificity of 
proglucagon maturation, the distribution of the pro- 
hormone convertases, PC1/3, PC2 and PC5/6, were com- 
pared in two cell lines that process proglucagon differ- 
ently. Both cell lines are derived from endocrine tumors 
arising in transgenic mice harboring a hybrid gene con- 
struct linking hormone promoter to a potent oncogene 
[ 191. The aTCl-6 cells process proglucagon in a manner 
similar to that found in pancreatic A-cells [20,21], 
whereas the STC-1 cells were claimed to express a set of 
peptides reminiscent of the intestinal L-cells [22,23]. 
2. Materials and methods 
2.1. Peptides 
Synthetic GLP-1(7-36)amide (tGLP-1) was purchased from Penin- 
sula Laboratories (San Carlos, CA). Partially purified glicentin and 
synthetic oxyntomodulin were prepared in our laboratory as previously 
described [24]. Glucagon was obtained from Novo Nordisk A/S 
(Bagsvaerd, Denmark). Mono[‘251]peptides (tGLP-1 and glucagon) 
were prepared as described [25]. 
2.2. Cell culture 
aTCl-6 cells [26] and STC-1 cells were kindly provided by S. Efrat 
(Albert Einstein College of Medicine, Bronx, NY) and D. Hanahan 
(University of California, San Francisco, CA). For reference purposes, 
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line, BHC9 [27] was kindly donated by F. Rad- 
Sup&ieure, Paris, France) and the mouse pitui- 
ta&AiTZO cells were obtained from X. Bertagna (CHU, Cochin-Port- 
the hyperplastic B-cell 
vanvi (Ecole Normale 
Royal, Paris, France). The cell lines were cultured in DMEM (aTCl-6, 
BHC9). DMEM/Ham’s F12 (AtT20) or RPMI-1640 (STC-1) media 
kuppl&ented with 10% fetal calf sekm, 100 U/ml pedicillin and 100 
,@ml streptomycin in an atmosphere of 5% CO, (7% CO* for AtT20) 
in air, at 37°C. 
2.3. Cell extraction and HPLC 
aTCl-6 and STC-1 cells were harvested from IO-cm Petri dishes in 
phosphate buffered saline, 0.7 mM EDTA, boiled for 3 min and ex- 
tracted in 0.5 M acetic acid. Cell extracts were subjected to high per- 
formance liquid chromatography (HPLC) as previously described [27]. 
Fractions were dried using a Speed-Vat concentrator and reconstituted 
in the radioimmunoassay buffer. 
2.4. Radioimmunoassays 
Glucagon-containing peptides were determined using antisera raised 
in rabbits. GAN antiserum and GOL antiserum are directed against he 
C-terminal and the central part of the glucagon molecule, respectively 
[24]. FAN antiserum recognizes the C-terminal region of oxyntomod- 
ulin/glicentin molecules [28]. tGLP-1 was measured using an antiserum 
(HER) produced by immunization with the synthetic N-terminal hep- 
tapeptide of tGLP-1, coupled to keyhole limpet hemocyanin (KLH) 
according to [28]. HER antiserum displayed 2% cross-reactivity with 
secretin and 5% with glucagon but no cross-reactivity with the full 
length GLP-1 nor with pituitary adenylate cyclase activating polypep- 
tide and vasoactive intestinal peptide. In all 4 radioimmunoassays, 
bound and free ligand were separated with dextran-coated charcoal and 
the intra- and inter-assay variance were within 15% for all assay sys- 
tems. Quantitative evaluations of the final processed peptides were 
performed using GAN antiserum for glucagon, FAN antiserum for 
glicentin and oxyntomodulin and HER antiserum for tGLP-1. 
2.5. Antisera to PCs and immunoblotting 
Rabbits were immunized against synthetic peptides coupled to KLH 
via a cysteine residue. For PC1/3, the N-terminal region corresponding 
to amino acids 84-93 [ 131, for PC2 the C-terminal amino acid sequence 
592-608 [12] and for PC5/6 the putative N-terminal region correspond- 
ing to amino acids 117-126 [17] were used. Cell and mouse intestinal 
mucosa samples were electrophoresed on 10% SDS-polyacrylamide gels 
and then electroblotted onto nitrocellulose membranes. PC products 
were detected by incubation with the antisera and revealed, using 
[?]protein A, by autoradiography. 
3. Results 
The HPLC profiles of aTCl-6 and STC-1 cell extracts 
(Fig. 2) analyzed by the different sequence-specific anti- 
sera to glucagon-related peptides clearly demonstrated 
the differential processing of proglucagon in these cell 
lines. In the aTCl-6 cells (Fig. 2A), glucagon repre- 
sented about 80% of the final processed peptides from 
the N-terminal moiety of the proglucagon precursor. 
Oxyntomodulin (recognized by FAN and GOL antisera) 
accounted for 10% of the glucagon-containing peptides. 
Two additional peaks, with retention times of 29.5 min 
and 33 min were also detected. The processing of the 
C-terminal part of the precursor, as assessed by tGLP-1 
measurement, was weak and represented only 1% of the 
glucagon-containing peptides. In the STC-1 cells (Fig. 
2B), the N-terminal moiety of the proglucagon precursor 
was partially processed into glicentin (32%), oxyntomod- 
ulin (37%), both recognized by GOL and FAN antisera, 
and glucagon (25%). In these cells, tGLP-1 represented 
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Fig. 1. Schematic representation of the cell-specific processing of pro- 
glucagon in pancreatic A-cells and in intestinal L-cells. End products 
in A-cells are glucagon and major proglucagon fragment (MPGF) and 
in L-cells, glicentin, oxyntomodulin, glucagon-like peptides 1 and 2 
(GLP-1 and GLP-2) and truncated GLP-1 (GLP-1(7-37) and GLP-1(7- 
36)amide). GRPP, glicentin-related pancreatic peptide; SPl, SP2, 
spacer peptides 1 and 2. The basic amino acids at the potential cleavage 
sites are also shown. 
46% of the glucagon-containing peptides. The overall 
amount of proglucagon-derived peptides in STC-1 cells 
was about 30-fold lower than those found in aTCl-6 
cells. 
Immunoblotting with an antiserum against the PC1/3 
enzyme (Fig. 3, top panel) identified a major band at 66 
kDa and a slower moving band (88 kDa) in both refer- 
ence cell lines, /3HC9 cells and AtT20 cells, but neither 
in the two proglucagon processing cell lines, aTCl-6 and 
STC-1 nor, in the ileal mucosa preparation. 
With the antiserum to PC2, a strongly labelled band 
(65 kDa) was observed in aTC1-6 cells and in/3HC9 cells 
(Fig. 3, middle panel). In contrast, an analogous but 
faintly immunostained band was detected in STC-1 cells 
and AtT20 cells but not in ileal mucosa sample. 
As shown in Fig. 3 (bottom panel), immunoblotting 
with PC5/6 antiserum revealed an immunoreactive band 
at 70 kDa in the different cell lines analyzed and in the 
ileal tissue sample. A 70 kDa protein was also detected 
with this antisera in adrenal and brain cortex extracts but 
not in the liver (data not shown). In the four cell lines, 
additional faster moving bands were apparent in the 30 
kDa range that were not detected in the tissue extracts. 
The identity of these 30 kDa bands is not know; it may 
represent non-specific immunostaining artifacts or 
breakdown products of the enzyme. 
4. Discussion 
The conversion of proglucagon to glucagon in pancre- 
atic A-cells and to glucagon-related peptides in intestinal 
L-cells is a multi-step mechanism involving endoprote- 
olytic cleavages of the precursor molecule at several 
basic sites (Fig. 1). However, in both cell types, pro- 
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glucagon is cleaved at a common site between the gli- 
centin and MPGF regions. Then, the extent to which 
subsequent cleavages occur differs between the cell types. 
In the dTCl-6 cell line, we show that glucagon is the 
major proglucagon-derived peptide produced, as previ- 
ously reported with the uncloned ccTC1 cells [21]. The 
HPLC profile of the glucagon-related peptides in aTCl- 
6 cells is consistent with the typical pattern described for 
pancreatic A-cells both in rat and human, including the 
presence of oxyntomodulin, the intermediary peptide be- 
tween proglucagon and glucagon [1,6,28]. Thus, in 
aTCl-6 cells, there is little further processing of the 
C-terminal region of the precursor, as assessed in our 
study by tGLP-1 determination, when the N-terminal 
region was further cleaved at both ends of the glucagon 
molecule. In the other cell line, STC-1, the proglucagon 
molecule, is processed more extensively in a manner 
which appears intermediate between the intestinal L-cell 
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2. HPLC profiles of aTCld cell (A) and STC-1 cell (B) extracts mon- 
itored with RIA using a central glucagon antiserum (GOL; o), a C- 
terminal glucagon antiserum (GAN, l ), a C-terminal oxyntomodulin 
/glicentin antiserum (FAN; A) and a N-terminal tGLP-1 antiserum 
(HER; 0). The arrows indicate the elution times of the peptide markers. 
OXM, oxyntomodulin. Experimental details are described in section 2. 
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Fig. 3. Western blots with PC113 (top panel), PC2 (middle panel) and 
PC5/6 (bottom panel) antisera. Cells and tissue extracts were subjected 
to SDS-PAGE followed by immunoblotting. Amounts of proteins used 
were 1OOpg each for the different cell lines and 800 pug for ileal mucosa. 
The migration of molecular size standards, expressed in kDa, are indi- 
cated. 
type and the pancreatic A-cell type [1,6,28]. Indeed, the 
two glucagon-containing peptides, glicentin and oxynto- 
modulin, as well as tGLP- 1, are predominant but, unlike 
the rodent L-cell type, glucagon is produced in similar 
amounts. In both cell lines, the differences in the respec- 
tive amounts of the glucagon-containing peptides, as de- 
termined by the centrally directed antiserum (GOL) and 
by the C-terminal glucagon (GAN) or the oxyntomod- 
ulin/glicentin (FAN) antisera, suggest the presence of 
peptides incompletely processed at their C-terminal end 
by specific exopeptidases uch as carboxypeptidase H 
that has been described in pancreatic A-cells [29]. 
Provided that the protein levels measured by im- 
munoblot analysis reflect the activity of the respective 
enzymes, the present data clearly show that the distribu- 
tion patterns of the three convertases are quite similar in 
the two cell lines except for PC2 which is much more 
abundant in the aTCl-6 cells than in the STC-1 cells. 
The high expression of PC2 along with the high glucagon 
content in the aTCl-6 cells suggests that this convertase 
might be implicated in the cleavage of proglucagon at 
both sides of the glucagqn molecule. 
PC1/3 is clearly revealed as two bands (88 and 66 kDa) 
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in both the insulin-secreting cells and the anterior pitui- 
tary cells, as previously reported [30,31]. This enzyme is 
not detectable in aTCl-6 and in STC-1 cells, suggesting 
that PC1/3 is not implicated in the maturation of pro- 
glucagon in the two proglucagon processing cell lines. 
PCY6, a new member of the subtilisin family identified 
by cDNA cloning [ 17,181, displays a widespread istribu- 
tion, as assessed by Northern blot analysis, over many 
mammalian tissues, with a high abundance in the gut and 
the adrenal glands [17,18]. Low levels of PC5 mRNA 
have been reported in several cell lines, including AtT20 
cells and the insulin-secreting jITC3 cells [18]. From the 
predicted amino acid sequence, we have raised an anti- 
serum to the putative N-terminal sequence of the mature 
protein. By immunoblotting, this new antiserum reveals 
a protein band of 70 kDa which is present with similar 
intensities in the two proglucagon processing cell lines. 
The same protein band is also detected in AtT20 cells, 
in the ileal mucosa (Fig. 3, bottom panel) and (not 
shown) in the adrenal glands and the brain cortex but not 
in the liver, in agreement with the reported distribution 
of PC5 mRNA [18]. The presence of PC5/6 in both pro- 
glucagon processing cells suggests that the enzyme might 
be responsible for some of the observed cleavages at the 
level of dibasic sites which occur in both cell lines, such 
as the KR (Lys-Arg) between glicentin and MPGF re- 
gions in the precursor, and therefore it would not be 
implicated in the differential processing that takes place 
in these cells. 
The present data suggest hat PC2 might be responsi- 
ble for the efficient processing of proglucagon into glu- 
cagon in the aTCl-6 cells, through the KR cleavages on 
both sides of the glucagon molecule, thus conferring to 
these cells their specificity as the A-cell type. The low 
level of PC2 in STC-1 cells would dramatically reduce 
the processing of the prohormone, revealing end prod- 
ucts that were in negligible amounts, compared to glu- 
cagon, in the aTCl-6 cells. Alternatively, some as yet 
uncharacterized enzyme(s) might be involved in the fur- 
ther processing of the C-terminal moiety of proglucagon 
(MPGF) in STC-1 cells and in intestinal L-cells. 
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